#USA #Annapolis #Phenomix Sciences #MyPhenome #Proto360 Health

Proto360 Health Partners with Phenomix Sciences for Obesity Management

On November 12, 2026, Proto360 Health announced a strategic partnership with Phenomix Sciences to enhance obesity care in employer programs. This collaboration aims to integrate the MyPhenome® genetic obesity test into Proto360's comprehensive metabolic care services, launched in conjunction with ObesityWeek® 2026. By incorporating genetic testing into treatment protocols for GLP-1 medications, Proto360 Health is pioneering a more accountable way to manage rising healthcare costs attributed to obesity treatment.

The Challenge of Managing Obesity

Obesity management is a growing concern in the healthcare sector, particularly in employer health benefits. Recent statistics reveal that GLP-1 medications now constitute 11.4% of annual claims, a significant increase from 6.9% in 2023. These medications can elevate employer health plan premiums by nearly 14% each year. Additionally, many patients discontinue treatment too early to realize substantive benefits; approximately two-thirds of those without type 2 diabetes stop their GLP-1 therapy within a year.

In response to these challenges, many employers are shifting their focus to more structured obesity care while requiring patients to engage with dietitians or lifestyle programs. However, the way GLP-1 prescriptions are decided still lacks personalization and precision in treatment, leading to numerous patients receiving ineffective care.

Integrating Genetic Testing into Obesity Treatment

The partnership brings exciting advancements, as the MyPhenome test developed by physician scientists at the Mayo Clinic, enables clinicians to understand the biological factors that contribute to each patient's obesity through a non-invasive cheek swab. Results from the genetic analysis guide physicians as they consider each employee's metabolic lab work and body composition data before prescribing GLP-1 medications.

John Mulligan, MD, founding partner of Proto360 Health, emphasized the importance of a holistic approach in prescribing medications for obesity. He stated, “A physician wouldn’t start someone on blood pressure or diabetes medication without a full diagnostic picture and regular follow-up, and obesity care should be held to the same standard.”

The partnership signifies the move towards precision medicine, where physicians can delve deeper into an individual’s unique genetic makeup and personalize treatment plans accordingly. This integration not only helps in better decision-making during the initial assessment but also tracks patient progress through various monitoring tools, including body composition scales, continuous glucose monitors, and wearables.

A Comprehensive Care Model

Proto360 Health is not just providing genetic testing; they designed a comprehensive metabolic care program that allows employers to manage GLP-1 benefits more effectively. By coupling genetic testing with continuous clinical oversight and lifestyle support, the program positions itself as a model for effective obesity management.

Katrina Mattingly, MD, another founding partner, highlighted an often frustrating aspect of GLP-1 treatment: the trial-and-error method that patients frequently face. The introduction of MyPhenome during initial assessments aims to eliminate this uncertainty, setting patients up for more effective treatments from the onset.

Furthermore, Phenomix Sciences' CEO, Mark Bagnall, pointed out that understanding the biological determinants of treatment responses is crucial for reducing excessive spending on obesity care and achieving measurable outcomes for employers.

Looking Ahead

As the healthcare landscape evolves, methods to manage obesity treatments are critical in ensuring sustainable healthcare benefits. With its pioneering partnership with Phenomix Sciences, Proto360 Health is taking significant steps toward providing more informed, guided, and tailored obesity care. This innovative model may soon become the blueprint for similar initiatives across the healthcare industry.

The partnership's announcement coincides with their presence at ObesityWeek® 2026, signalling the start of an essential dialogue about transforming obesity management into a more effective, scientifically-backed approach.

For more information about the services provided by Proto360 Health and the integration of MyPhenome in their treatment protocols, visit proto360health.com.

About Proto360 Health

Proto360 Health, LLC, is a metabolic care platform conceived by certified obesity medicine physicians to ensure consistent care for metabolic diseases. Combining medical expertise and personalized treatment protocols, Proto360 aids medical practices and employers in effectively managing obesity throughout every treatment phase.

About Phenomix Sciences

Phenomix Sciences focuses on transforming obesity care with its proprietary genetic testing and advanced analytics. By delivering detailed, individualized insights into patient responses to weight loss interventions, the company aims to reshape obesity treatment tailored to each patient’s biology. With backing from Health2047, part of the American Medical Association, Phenomix is at the forefront of innovative approaches to obesity therapy.